Abiopharma

Financial Statements and Related Announcement: Discrepancies between unaudited and audited accounts

New Form DEFA14A - SIERRA BANCORP <b>Filed:</b> 2026-04-07 <b>AccNo:</b> 0001104659-26-040185 <b>Size:</b> 424 KB

ASCENDIS PHARMA A/S (ASND) Files Form 6-K

(50% Neutral) ARLO TECHNOLOGIES, INC. (ARLO) Announces Regulatory Update

New Form DEF 14A - SIERRA BANCORP <b>Filed:</b> 2026-04-07 <b>AccNo:</b> 0001104659-26-040182 <b>Size:</b> 3 MB

CALEDONIA MINING CORP PLC (CMCL) Files Form 6-K

New Form 4/A - GREENLIGHT CAPITAL RE, LTD. <b>Filed:</b> 2026-04-07 <b>AccNo:</b> 0001385613-26-000052 <b>Size:</b> 5 KB

Natera - 20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform

CHUNGHWA TELECOM CO LTD (CHT) Files Form 6-K

New Form PRE 14A - OFS Capital Corp <b>Filed:</b> 2026-04-07 <b>AccNo:</b> 0001487918-26-000028 <b>Size:</b> 1 MB

Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential

KRISPY KREME® Celebrates Malcolm in the Middle Return with Exclusive Specialty Pack

Lifezone Produces First-Ever Platinum, Palladium and Rhodium from its U.S. PGM Recycling Project

Linde Announces First Quarter 2026 Earnings and Conference Call Schedule

20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform